Ruti Aga and the Six-Year Ban: Methylprednisolone, an Old Prescription Pad, and Where Medical Support Systems Collapse

On 10 September, the Athletics Integrity Unit (AIU) — World Athletics' independent integrity body — announced a six-year ban for Ruti Aga. Of everything in the file, the detail that deserves the longest pause is not the name of the substance. It is the prescription pad. The document Aga submitted to prove she had been treated for a knee injury was written on an old prescription pad from a clinic. That clinic confirmed to the AIU that it did not issue the prescription. The professional registry confirmed that the person who signed it holds no medical licence. The person who signed it is a family member. And the clinic where that person claimed to have worked confirmed that no one by that name had ever appeared on its staff list. Six years is the product of an addition that no reader could reconstruct from the substance alone. Two years for the presence of a prohibited substance in a sample. Four years for tampering with evidence during results management. Served consecutively, not concurrently. I have followed Aga since before she became a name anyone had to look up. On the afternoon of 3 March 2026, I sat in the grandstand along the finish straight of the Tokyo Marathon with one notebook and four pencils, logging split times for the women's lead pack. Nothing about that afternoon suggested a doping case. That is why I want to write this differently from most dispatches: to point at the place where a thin support system turned a survivable medical incident into an unsurvivable ruling. An athlete at the summit, not on the fringe Aga does not belong to the category of second-tier athletes caught through ignorance. She won the 2026 Tokyo Marathon — one of the six World Marathon Majors. She has three runner-up finishes at World Marathon Majors level. Within the Ethiopian women's road scene of 2026–2026, that is the record of someone in the genuine elite, not the reserve pool. The result that triggered the case was a victory at a half marathon in China in March. The source does not disclose the actual time from that race. For an analyst, that is a significant gap: without a time, the result cannot be placed against her personal best, the course profile, the weather, or the world standing. Any inference about the sporting meaning of that win is speculation, and I will leave it as speculation. Its non-sporting meaning is far clearer. Half marathons in China, for East African distance runners, are typically appearance-fee races — income that sits outside the World Marathon Majors system. They are also a tier of race with lower testing density and a denser calendar. That economic structure did not create the case, but it explains why the case surfaced there rather than in Berlin or London. Methylprednisolone is not what headlines usually call a steroid This is where I want to slow down most, because most English-language reporting calls methylprednisolone a banned steroid. That phrasing is not wrong in ordinary vocabulary, but it is wrong in classification, and the distortion shifts the entire way a reader perceives the severity of the case. Methylprednisolone is a synthetic glucocorticoid — a corticosteroid, an anti-inflammatory class. It sits in WADA class S9, and that class is prohibited in competition only, not out of competition. More importantly, it is a Specified Substance — a category WADA acknowledges is more plausibly linked to inadvertent use or genuine therapeutic use. It belongs to the corticosteroid family, not the anabolic family. It is not used to add muscle mass or to accelerate recovery across a training block. It is an anti-inflammatory, injected into a knee joint in everyday sports-medicine practice, in every orthopaedic clinic from Nagoya to Addis Ababa. That distinction sets the baseline sanction. For a Specified Substance, the baseline is two years, with a route to reduction if intent to enhance performance cannot be established. For an anabolic steroid, the baseline is four years and the mitigation route is far narrower. Put differently: the substance half of this case was always the soft half. The hard half sits on the prescription pad. Two plus four, not six My spreadsheet in Nagoya has one column I always fill before any other: the days column. Days of treatment, days off, days between appearances. Nagoya taught me that a hand-kept spreadsheet is where data first learns to speak — and it only speaks when you split a total into the parts that add up to it. Six years is a total. Split apart, it is two plus four. Four years is the penalty for interfering with results management — tampering. Under the World Anti-Doping Code this is an independent violation, not an aggravating circumstance of the original offence. It is adjudicated separately, carries its own penalty range, and under the rules on multiple violations, sanctions are served consecutively rather than concurrently. Which means the fabrication of evidence was punished twice as heavily as the presence of the substance. This is the central governance lesson of the case, and most reporting skips it. The public reads six years for doping. The reality is two years for an anti-inflammatory, plus four years for forged paperwork. Had Aga declared the knee injection honestly and applied for a Therapeutic Use Exemption (TUE) through the proper process, the most likely scenario is no violation at all, or a far lighter violation that would not have stacked. What destroyed her career was not the injection. It was the response to the injection. How airtight the evidence chain is The AIU's finding does not rest on inference. The evidence chain has at least four independent links, and any one of them alone would have dismantled the explanation. First, the clinic named on the prescription confirmed directly to the AIU that it did not issue the document. Second, the professional registry confirmed that the signatory holds no medical licence. Third, the clinic where the signatory claimed to have worked confirmed that the person had never been on staff. Fourth, the signatory is a family member, and that person admitted to using an old prescription pad left over from a former workplace. These four links do not depend on one another. Breaking one would not have saved the other three. In investigative terms, this is the strongest evidentiary structure an anti-doping body can hold: direct third-party confirmation, a licence check, and an admission. What stands out is the speed. Verifying a prescription with the issuing clinic is now standard procedure, not a special investigation. A forged prescription today has a lifespan measured in days, not months. Anyone who advised Aga to build that defence had fundamentally misjudged the AIU's verification capacity. The amateurism of the fabrication is itself a diagnosis. No one in Aga's support group had sports-integrity expertise. No lawyer specialising in results management. No one to tell her that a late TUE with an honest declaration costs far less than a forged prescription. A word on the TUE mechanism, because it is the centre of the story and almost never explained. A Therapeutic Use Exemption is a real administrative process, designed precisely for this situation: an athlete with a valid medical indication for a substance on the prohibited list, who needs permission to use it. The process requires a diagnostic file, the name of the substance, the route of administration, the dose, and the timing relative to competition. For glucocorticoids, route and timing are the two decisive variables, because class S9 is prohibited in competition only. An intra-articular knee injection some weeks before competition, with an indication on file and a retroactive TUE, is a fully defensible situation. An injection with no file, no TUE, then explained with a forged prescription, is not defensible at all. The distance between those two situations is not a medical distance. It is a paperwork distance. The other side of the ledger: how the Ethiopian system absorbs the loss From a competition standpoint, the impact is close to zero. The Ethiopian and Kenyan women's marathon pipelines are deep enough that removing one individual creates almost no gap in national performance structure. The list of Ethiopian women running under 2:20 is long enough that one withdrawn slot changes no medal projection. Aga is a replaceable node in an extraordinarily dense production pipeline. There is another kind of loss that never shows up on a results sheet: the brand value of the Ethiopian road-running label. That label has commercial worth to race organisers, sponsors and agents. Every published doping case erodes it slightly, and a case featuring a fake doctor inside the family erodes it more sharply than usual, because it is memorable and it travels. I do not read this case as evidence of a systemic Ethiopian doping problem. It is an individual case, poorly handled, inside a system deep enough that it has no need of reckless options. But it exposes a real weakness: athletes in the East African distance-running supply chain rarely have dedicated integrity counsel. When something goes wrong, they handle it themselves, or they let a relative handle it. On jurisdiction, one point is worth stating plainly because much coverage conflates it: the case was handled by the AIU, not by a national federation, and resolved under the World Anti-Doping Code rather than under a race organiser's rules. That means the Chinese half marathon result is almost certainly annulled, prize money forfeited, and the reach extends well beyond a single race. The contrarian read: the ruling is not unjust, but the right question is being asked in the wrong place Most commentary I read in the two days after the AIU announcement fell into two camps. One said six years is excessive for an anti-inflammatory. The other said doping deserves a lifetime ban. Both camps skip the structure of the ruling. For me the issue sits elsewhere than whether six years is heavy or light. Those six years were generated by conduct unrelated to sporting performance. Aga was not punished heavily for running faster because of medication. She was punished heavily for submitting a forged document. Under the Code's logic those are two different offences, and the second is the heavier one. That is legally correct and has a sound rationale: if fabricating evidence were not penalised more heavily than the underlying violation, the system would collapse, because everyone would have an incentive to fabricate. But it produces a communications paradox: an athlete can lose a career over conduct the public does not regard as doping. There is one conflicting hypothesis I have to raise, because it is the only one that could have lightened the ruling had it been established: if the methylprednisolone knee injection was genuine treatment, correctly indicated, delivered intra-articularly close to competition, then the substance half could have been explained by a retroactive TUE. In that scenario, the only remaining violation is the forged paperwork — still four years, but not stacked onto two, and the competition result might not have been annulled. The source does not state the route of administration or the timing of the injection. That data is missing, and I cannot conclude on the AIU's behalf. One further possibility belongs on the table: Aga's record could be reviewed retrospectively. When a case concludes with a tampering finding, long-term storage samples and biological passport data are often revisited. For Aga that opens an additional exposure: older results could be put back into question. The source does not address it, and I mark it as a low-probability scenario rather than a conclusion. Data limitations I need to be explicit about which parts of this article stand on data and which do not. Confirmed: the name of the substance, the S9 classification, the six-year term, the two-plus-four structure, the 10 September start date, and the details of the non-existent clinic and the unlicensed signatory. Not confirmed: the specific year of the positive test and of 10 September; the performance at the Chinese half marathon; the route of administration of methylprednisolone; the timing of the injection relative to competition; Aga's official personal best during her peak period. My inferences rather than facts: that the Chinese half marathon was an appearance-fee race; that Aga's agent or manager was involved in assembling the file; that she will not attempt a comeback. The perfectionist's delay turns out to be a form of precision. I held this piece back an extra day to re-verify the classification of methylprednisolone, because calling the substance class wrong would make every downstream assessment of the sanction wrong too. Writing insufficient data in one place is how the remaining places earn their credibility. What will remain after the news cycle passes Aga is 32. For women's marathoners the peak window commonly extends to around 35, sometimes beyond. A six-year ban starting on 10 September returns her to eligibility at roughly 38. Theoretically, women's marathoners do still compete at elite level at that age. Probabilistically, the chance of returning to a World Marathon Majors podium after six years without racing is very low. This sanction ends a career; it does not pause one. The financial damage carries the same terminal quality. The Chinese half marathon result is almost certainly annulled, taking the prize money with it. For six years there are no World Marathon Majors invitations, no appearance fees, no sponsorship contracts. The three core revenue streams of an elite marathoner vanish simultaneously. Morality clauses in sponsorship contracts, standard industry practice, will be invoked faster than the AIU's own ruling landed. The most durable loss sits outside money. It is the story. A corticosteroid positive, handled properly, could have ended with a short notice and a reminder about TUE procedure. The story that will persist instead is an image of a clinic that did not exist and a relative who signed the form. That detail will follow Aga longer than any result she produced. The body betrays no one; it only reflects what we chose to overlook. In this case what was overlooked was not a clinical signal. It was a procedural step: obtaining a Therapeutic Use Exemption before the injection, or declaring it honestly afterwards. As someone who works in injury analysis, I take one lesson from this case and I want it at the end rather than the beginning: medical records are part of the competition record. In Japan, where I live and work, an orthopaedic clinic will not inject a corticosteroid into an athlete's knee without documentation, without dates, without the name of the practitioner. That rigour is not redundant bureaucracy. It is what protects an athlete from her own panic when a test result comes back positive. In sport's 112 days of silence, what I heard most clearly was the cracking of the body. In this case, what cracked was not a ligament. It was a chain of small decisions, each of which looked reasonable at the time, adding up to a six-year ban. The next athlete in a similar situation will not need a better lawyer. They will need a clearer process, and someone with enough courage to tell them that telling the truth is always cheaper than covering it up. Will the system provide that before the next case arrives?